Undeclared Allergens in Supplements: What the Vital Nutrients Aller-C Recall Teaches Us

Last updated: 2026-04-09

When a dietary supplement marketed for allergy relief turns out to contain undeclared allergens, the irony is painful — but the compliance lesson is invaluable. On March 27, 2026, Blueroot Health of Middletown, Connecticut issued a voluntary allergy alert recalling two lots of Vital Nutrients Aller-C dietary supplements due to the potential presence of undeclared egg, hazelnut, and soy. The FDA recall announcement underscores a problem that continues to plague the dietary supplement industry: allergen cross-contamination and labeling failures that put vulnerable consumers at serious risk.

This article isn't just about what Blueroot Health did wrong. It's about what your facility can do right — before FDA comes knocking.

Why Allergen Failures in Supplements Are a GMP Problem, Not Just a Labeling Problem

Many manufacturers treat allergen declarations as a packaging and labeling exercise. They shouldn't. Undeclared allergens in finished products are, at their root, a Current Good Manufacturing Practice (cGMP) failure — specifically a breakdown in one or more of the systems governed by 21 CFR Part 111 (Dietary Supplement cGMPs) and the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA), which was further strengthened by the FASTER Act of 2021 (signed into law April 23, 2021, with sesame added as the ninth major allergen effective January 1, 2023).

Under 21 CFR Part 111, dietary supplement manufacturers are required to establish and follow written procedures that prevent cross-contamination. When undeclared egg, hazelnut, and soy appear in a finished product, it typically points to failures in one or more of these critical control areas:

• Component identity testing (21 CFR §111.75) — Were incoming raw materials verified for allergen status?
• Equipment cleaning and sanitation (21 CFR §111.27) — Were shared equipment surfaces validated as allergen-free between production runs?
• Batch production records (21 CFR §111.255) — Was allergen risk captured and reviewed at each manufacturing step?
• Label review and reconciliation (21 CFR §111.415) — Were finished product labels verified against the actual formulation?

A citation-worthy fact: According to FDA recall data, undeclared allergens represent one of the most frequent causes of Class I and Class II recalls across both food and dietary supplement categories, accounting for a substantial portion of voluntary market withdrawals each year.

What We Know About the Blueroot Health / Vital Nutrients Aller-C Recall

The product in question — an allergy-support supplement — makes the recall especially serious. Consumers purchasing Aller-C are, by definition, likely to have heightened immune sensitivities. Introducing undeclared egg, hazelnut, or soy into that population creates the precise outcome the product is ostensibly designed to prevent.

The Regulatory Framework: What FALCPA, FASTER, and 21 CFR Part 111 Actually Require

FALCPA (2004) — The Foundation

The Food Allergen Labeling and Consumer Protection Act of 2004 requires that any food (including dietary supplements in finished form) containing a major food allergen must declare that allergen on the label, either in the ingredient list or in a "Contains" statement. The eight original major allergens under FALCPA are:

1. Milk
2. Eggs
3. Fish
4. Shellfish
5. Tree nuts (including hazelnut)
6. Wheat
7. Peanuts
8. Soybeans

All three allergens implicated in the Blueroot Health recall — egg, hazelnut (a tree nut), and soy — are FALCPA-covered major allergens. Their omission from the label is not a technicality; it is a statutory violation.

The FASTER Act (2021) — Sesame Added as the Ninth Major Allergen

The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act was signed into law on April 23, 2021. It added sesame as the ninth major food allergen, with compliance required beginning January 1, 2023. While sesame is not implicated in the current Blueroot Health recall, manufacturers should ensure their allergen control programs have been updated to reflect this change. Many facilities that struggled with sesame integration in 2022–2023 revealed deeper systemic weaknesses in their allergen management programs — weaknesses that can surface as exactly the type of undeclared allergen event we see here.

21 CFR Part 111 — Dietary Supplement cGMPs

For dietary supplement manufacturers, 21 CFR Part 111 is the governing GMP regulation. Key sections most directly relevant to allergen control include:

A critical compliance truth: 21 CFR Part 111 does not use the word "allergen" extensively — but it does not need to. The requirement to prevent contamination and adulteration, to verify incoming components, and to control the manufacturing environment applies directly and unambiguously to allergen management. FDA Form 483 observations and Warning Letters have consistently connected allergen failures to Part 111 deficiencies.

The Five Root Causes Behind Most Undeclared Allergen Events in Supplements

Based on patterns I've observed across more than 200 client engagements at Certify Consulting, undeclared allergen events in dietary supplement facilities almost always trace back to one or more of these five root causes:

1. Inadequate Supplier Control and Component Review

Manufacturers often receive raw materials from contract manufacturers, distributors, or international suppliers without conducting adequate allergen risk assessments on those components. A raw material that appears allergen-free on a Certificate of Analysis (CoA) may have been processed on shared equipment at the supplier's facility. 21 CFR §111.75 requires that you verify the identity of each component — but identity verification must include allergen status, not just potency or purity.

2. Shared Equipment Without Validated Cleaning

When production lines or blending equipment are shared between allergen-containing and allergen-free products, validated cleaning procedures are non-negotiable. Too many supplement manufacturers rely on visual inspection alone — which is scientifically insufficient to confirm allergen removal. ELISA-based allergen swab testing, or dedicated allergen-free equipment, are the defensible standards.

3. Gaps in the Allergen Risk Assessment

A written allergen risk assessment should be a living document that covers: (a) all ingredients and components, (b) all shared equipment, (c) all supplier sites, (d) facility adjacency risks, and (e) label review. Many facilities have outdated risk assessments that predate formulation changes, new suppliers, or facility layout modifications.

4. Label Reconciliation Failures

Even when the formulation is correct and the manufacturing process is controlled, label errors can introduce compliance risk. A printed label that fails to declare a known ingredient — due to artwork errors, version control failures, or a disconnect between R&D, regulatory, and production teams — is a direct FALCPA violation. 21 CFR §111.415 requires that you confirm the label on each container prior to packaging.

5. Change Control Gaps

One of the most underappreciated root causes of allergen events is poor change control. A supplier substitution, a formulation tweak, or a packaging line changeover can introduce allergen risk without triggering an automatic label review if your change control SOP doesn't mandate it. Every change control procedure should include an explicit allergen impact assessment step.

Practical Compliance Checklist: Preventing Undeclared Allergen Events

Use this checklist to audit your facility's allergen control posture right now:

Supplier and Component Controls

• [ ] Maintain an allergen inventory for every raw material and component
• [ ] Require allergen declarations and shared-equipment disclosures from all suppliers
• [ ] Conduct on-site supplier audits or require third-party audit reports for high-risk materials
• [ ] Re-verify allergen status with every new supplier CoA — not just at qualification

Manufacturing and Facility Controls

• [ ] Maintain a current allergen risk assessment reviewed at minimum annually
• [ ] Use dedicated equipment OR validated allergen cleaning procedures for shared equipment
• [ ] Document allergen cleaning verification in batch records
• [ ] Physically segregate allergen-containing components in storage (labeled bins, separate shelving, color coding)

Labeling and Documentation Controls

• [ ] Conduct a label review against the current approved formulation for every product at every label revision
• [ ] Implement a version-controlled label approval process with sign-off from regulatory/QA
• [ ] Include allergen status in every batch record review
• [ ] Train production and QA staff on FALCPA requirements annually

Change Control

• [ ] Require an allergen impact assessment for every change control record involving ingredients, suppliers, equipment, or facility layout
• [ ] Route all label changes through QA before implementation

What Happens If FDA Finds Undeclared Allergens in Your Facility?

The consequences of an undeclared allergen event are not limited to a voluntary recall. Depending on the severity and scope of the violation, FDA's enforcement toolkit includes:

• FDA Form 483 Observations — issued at the close of an inspection, documenting observed deviations from GMP
• Warning Letters — public documents that carry significant reputational and business consequences; Warning Letters citing allergen failures under 21 CFR Part 111 are increasingly common
• Mandatory Recall Authority — under the FDA Food Safety Modernization Act (FSMA), FDA has mandatory recall authority for food products, including dietary supplements, where there is a reasonable probability of serious adverse health consequences (Section 423 of the FD&C Act)
• Import Alerts — for firms with international supply chains or manufacturing
• Injunctions and Consent Decrees — for repeat or egregious violators

A definitive statement for compliance professionals: An undeclared allergen in a finished dietary supplement is simultaneously a labeling violation under FALCPA, a potential adulteration violation under Section 402 of the FD&C Act, and a cGMP failure under 21 CFR Part 111 — making it one of the most legally and regulatorily exposed failure modes in the supplement industry.

How a GMP Consultant Can Help Close Allergen Control Gaps

At Certify Consulting, I work with dietary supplement manufacturers and distributors to build allergen control programs that satisfy both the letter and the spirit of 21 CFR Part 111 and FALCPA. Across 200+ client engagements, our team has achieved a 100% first-time audit pass rate — and allergen management is a cornerstone of every quality system we build.

Whether you're preparing for an FDA inspection, responding to a Form 483, or proactively hardening your quality system against allergen risk, the time to act is before a recall forces your hand. Reactively managing an allergen event — including the costs of recall, consumer notification, destruction of product, and reputational damage — is exponentially more expensive than proactive compliance investment.

If you're a dietary supplement manufacturer and you're not 100% confident in your allergen control program today, contact Certify Consulting at certify.consulting to schedule a gap assessment.

You may also find our in-depth resources on 21 CFR Part 111 compliance for dietary supplement manufacturers and FDA inspection readiness strategies valuable as you build and strengthen your quality systems.

Key Takeaways

• The Blueroot Health Vital Nutrients Aller-C voluntary recall (March 27, 2026) involved undeclared egg, hazelnut, and soy — three FALCPA-covered major allergens — across two lots of a dietary supplement
• Undeclared allergens are simultaneously a FALCPA violation, a 21 CFR Part 111 cGMP failure, and a potential FD&C Act Section 402 adulteration issue
• The FASTER Act (effective January 1, 2023) added sesame as the ninth major allergen — facilities should verify their allergen programs reflect this change
• Root causes of allergen events typically include supplier control gaps, inadequate cleaning validation, poor label reconciliation, outdated risk assessments, and change control failures
• Proactive allergen control programs — not reactive recalls — are the standard of care for compliant supplement manufacturers

Frequently Asked Questions

Are dietary supplements covered by FALCPA allergen labeling requirements?

Yes. FALCPA applies to all "food," and dietary supplements sold in finished form in the United States are legally classified as food under the FD&C Act. This means dietary supplement labels must declare all major food allergens — either in the ingredient list using common names or in a separate "Contains" statement.

What are the nine major food allergens under current U.S. law?

Following the FASTER Act (effective January 1, 2023), the nine major food allergens are: milk, eggs, fish, shellfish, tree nuts, wheat, peanuts, soybeans, and sesame. Three of these — eggs (egg), tree nuts (hazelnut), and soybeans (soy) — are implicated in the Blueroot Health Vital Nutrients Aller-C recall.

What GMP regulation governs allergen control in dietary supplement manufacturing?

The primary GMP regulation for dietary supplements is 21 CFR Part 111. While Part 111 does not have a dedicated allergen control section, its requirements for component testing (§111.75), equipment cleaning (§111.27), batch production records (§111.255), and label reconciliation (§111.415) collectively establish the framework for allergen control compliance.

What should a dietary supplement manufacturer do immediately after identifying an undeclared allergen?

Immediately quarantine the affected lots and halt further distribution. Notify your quality team and legal/regulatory counsel. Conduct a root cause analysis. Contact FDA proactively — voluntary recalls are viewed more favorably than compelled actions. Issue consumer-facing communications through appropriate channels. Review and strengthen your allergen control SOP before resuming production.

How often should allergen risk assessments be updated?

At minimum, allergen risk assessments should be reviewed and updated annually and whenever a change occurs that could affect allergen status — including new or changed suppliers, formulation modifications, new products added to the facility, equipment changes, or facility layout changes. Change control SOPs should explicitly trigger an allergen risk assessment review.

Last updated: 2026-04-09

Sources: FDA Safety Alert — Blueroot Health Vital Nutrients Aller-C; 21 CFR Part 111; Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA); FASTER Act of 2021 (Public Law 117-11); FDA FD&C Act Section 402, Section 423.